A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Clinical trial NCT05325346 · COMPLETED

Trial details

NCT number: NCT05325346
Sponsor: Veralox Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Heparin-induced Thrombocytopenia

Start date: 2022-03-07
Primary completion: 2022-04-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.